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Abstract
Glioblastoma Multiforme (GBM) is a malignant astrocytic tumor associated with low survival rates because of aggressive
infiltration of tumor cells into the brain parenchyma. Expression of the actin binding protein a-actinin has been strongly
correlated with the invasive phenotype of GBM in vivo. To probe the cellular basis of this correlation, we have suppressed
expression of the nonmuscle isoforms a-actinin-1 and a-actinin-4 and examined the contribution of each isoform to the
structure, mechanics, and motility of human glioma tumor cells in culture. While subcellular localization of each isoform is
distinct, suppression of either isoform yields a phenotype that includes dramatically reduced motility, compensatory
upregulation and redistribution of vinculin, reduced cortical elasticity, and reduced ability to adapt to changes in the
elasticity of the extracellular matrix (ECM). Mechanistic studies reveal a relationship between a-actinin and non-muscle
myosin II in which depletion of either a-actinin isoform reduces myosin expression and maximal cell-ECM tractional forces.
Our results demonstrate that both a-actinin-1 and a-actinin-4 make critical and distinct contributions to cytoskeletal
organization, rigidity-sensing, and motility of glioma cells, thereby yielding mechanistic insight into the observed correlation
between a-actinin expression and GBM invasiveness in vivo.
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Introduction
Glioblastoma Multiforme (GBM) is a high-grade astrocytoma
characterized by aggressive invasion of individual tumor cells into
the brain parenchyma [1]. The diffuse infiltration of GBM tumors
along vasculature and white matter tracts in the central nervous
system makes complete resection virtually impossible, giving rise to
a mean survival time from diagnosis of only 1–2 years, even with
aggressive therapy. The remarkable invasiveness of GBM tumors
is attributed in part to the capacity of the constituent tumor cells to
remodel the extracellular matrix (ECM), which is made possible by
integrin upregulation [2], matrix metalloprotease (MMP)-mediat-
ed proteolysis [3], and de novo secretion of ECM proteins [4].
This remodeling also depends on the ability of the tumor cells to
generate actomyosin-based contractile forces, which have been
observed in other systems to facilitate ECM fibril remodeling
during migration, thereby providing contact guidance cues to
invasive cells [5]. The importance of non-muscle myosin II
(NMMII) in glioma invasiveness has been demonstrated by studies
where inhibition of myosin light chain kinase (MLCK) completely
abrogated glioma motility [6].
To explore potential connections between ECM-encoded
signals, cellular contractility, and tumor progression, we recently
investigated the role of ECM rigidity (stiffness) in controlling
behaviors of glioma cells relevant to growth and spread [7]. We
demonstrated that the adhesion and cytoarchitecture of a variety
of glioma cell culture models are indeed sensitive to ECM stiffness,
and that this microenvironmental parameter can profoundly
influence cell motility and proliferation. Moreover, NMMII is
specifically required for this rigidity sensitivity, with inhibition of
NMMII abrogating stiffness-dependent differences in adhesion
and rescuing cell motility on highly compliant ECMs. While this
study clearly established a connection between ECM-based
mechanical cues, tumor cell adhesion and migration, and NMMII
activity, the underlying molecular mechanisms remain incom-
pletely understood.
Focal adhesions (FAs) play a central role in transducing
mechanical signals between the cytoskeleton and ECM [8]. In
the case of GBM specifically, a comparative study of in vitro
migration and invasion across ten human GBM cell lines revealed
that levels of the FA and actin-binding protein a-actinin correlates
directly with biological aggressiveness [9]. The field’s understand-
ing of a-actinin function in this context has been complicated by
the relatively recent discovery that four distinct isoforms exist in
humans: the nonmuscle isoforms 1 and 4 and the muscle-specific
isoforms 2 and 3. While both a-actinin-1 and a-actinin-4 have
been reported to localize along stress fibers [10], a-actinin-1 also
localizes to FAs and cell-cell contacts [11], and a-actinin-4 is also
enriched at the leading edges of invading cells [12]. Further,
immunohistochemical analysis of human tumors demonstrates
that the cytoplasmic localization of a-actinin-4 accurately predicts
an infiltrative phenotype and poor clinical prognosis [13,14,15].
While the above studies clearly establish that both a-actinin-1
and -4 contribute to tumor invasion and metastasis, the
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gical properties remains unclear. For example, siRNA-mediated
knockdown of a-actinin-1 increases motility and tumorigenicity of
fibroblasts, consistent with a role in stabilizing cell-ECM adhesive
contacts [16,17]. In intestinal epithelial cells, suppression of
a-actinin-1, but not a-actinin-4, inhibits deformation-induced
ERK phosphorylation and proliferation [18], reflecting the role of
a-actinin-1 in linking the cytoskeleton to the extracellular matrix
(ECM). In ovarian carcinoma cells, a-actinin-4 knockdown leads
to reduced motility and invasion [13], whereas mice genetically
deficient in a-actinin-4 exhibit increased lymphocyte chemotaxis
[19]. This heterogeneity of findings illustrates two broader points:
First, the role of each isoform is highly cell-type specific, making it
difficult to extrapolate these studies to human glioma cells. Second,
particularly if a-actinin is to be pursued as a drug target, the field
could benefit from additional quantitative and molecular-scale
insight into how each isoform contributes to biophysical
interactions between tumor cells and the ECM, including
adhesion, contractility, and mechanotransduction.
Here we seek to address both of these gaps in our understanding
of a-actinin function by investigating the contributions of a-
actinin-1 and a-actinin-4 to the structure, mechanics, and motility
of human glioma cells. We find that siRNA-mediated suppression
of either isoform reduces random cell migration speed and alters
the expression and localization of the FA protein vinculin.
Strikingly, suppression of either a-actinin isoform reduces ECM
rigidity sensitivity and alters responses to pharmacologic inhibition
of MLCK and Rho-associated kinase (ROCK). We attribute these
differences to alterations in NMMII expression and modulation of
contractility through interactions between MLCK and individual
a-actinin isoforms. Taken together, our results demonstrate that
both a-actinin-1 and a-actinin-4 make critical and distinct
contributions to cytoskeletal organization, rigidity-sensing, and
motility of glioma cells.
Materials and Methods
Cell Culture and RNA Interference
U373-MG human glioma cells were obtained and cultured
as previously described [7]. Cells were plated either on glass
coverslips or tissue culture polystyrene coated with bovine collagen
I (Inamed Biosciences) or on collagen-coated polyacrylamide (PA)
hydrogels attached to glass coverslips (see below). To suppress a-
actinin expression, cells were transfected with isoform-specific a-
actinin siRNA sequences (siACTN1 or siACTN4) or non-targeting
sequences (siCTL) (Santa Cruz, CA) per manufacturer’s specifi-
cations. For MLCK and ROCK inhibition studies, cells were
incubated with either ML7 (Calbiochem), Y27632 (Calbiochem)
or blebbistatin (Sigma) at 10 mM final concentration. For cell
motility experiments, cells were incubated with drug for 1 hour
prior to acquisition of time-lapse images.
Immunofluorescence and Western Blots
Immunofluorescence [7,20] utilized previously validated primary
(mouse anti-a-actinin-1 (1:200, Santa Cruz); mouse anti-a-actinin-4
(1:250, Abcam); mouse anti-vinculin (1:200, Sigma)) and secondary
antibodies (Alexa Fluor 543 goat anti-mouse IgG; Alexa Fluor 543
donkey-anti-goat IgG (1:500, Invitrogen)). F-actin and nuclear
stains utilized Alexa Fluor 488-phalloidin (1:200, Invitrogen) and
DAPI (1:500, Invitrogen), respectively. Immunoblots followed
manufacturer specifications (Invitrogen Western Blot kit), using
previously validated primary antibodies ((a-actinin-1 (1:500, Santa
Cruz); a-actinin-4 (1:500, Santa Cruz); NMMII (1:500, Santa
Cruz); vinculin (1:500, Sigma); phosphorylated MLC (pMLC)
(1:500, Cell Signaling); pY397FAK (1:500, Invitrogen); GAPDH
(1:20000, Sigma)) and HRP-conjugated secondary antibodies (goat-
anti-mouse, donkey-anti-goat or goat-anti-rabbit (Invitrogen)),
followed by TMB chromogenic substrate (Invitrogen). For pMLC
blots, chemiluminescent rather than colorimetric detection was
performed according to manufacturer protocols. After development
and scanning, band intensities were quantified using ImageJ (NIH).
Image Acquisition and Analysis
Imaging was performed using a Nikon TE2000E2 microscope
equipped with an incubator chamber for controlled temperature,
humidity, and CO2. Images were recorded with a CCD camera
(Photometrics CoolSNAP HQ2) interfaced to image acquisition
software (Compix SimplePCI). Cell spreading areas were measured
using ImageJ (NIH) by manually tracing the projected outlines of
50–100 cells per condition. Confocal images were obtained with a
Zeiss LSM510 microscope. For quantifying size distribution of FAs,
confocal images of vinculin stained cells (10 cells per condition)
were thresholded (ImageJ) and quantified for number and size of
FAs. FA circularity, defined as 4p * (area/perimeter
2), ranges
between 0 and 1, with a value close to 0 indicating an oblong
morphology and a value of 1 indicating a perfectly circular
morphology.Formotilitymeasurements,cellswereimagedevery15
minutes at 106 magnification for .6 hours and quantified using
manual tracking in ImageJ. The data was further processed to
obtain mean speed for a given condition.
Synthesis of Polyacrylamide ECMs and Traction Force
Microscopy (TFM)
Polyacrylamide ECMs of defined stiffness were synthesized by
polymerizing and crosslinking predetermined ratios of acrylamide
and bisacrylamide [7,21]. For TFM experiments [22,23], Texas
red-labeled microspheres (1 mm diameter, Invitrogen) were includ-
ed in the acrylamide/bisacrylamide solution prior to polymeriza-
tion. Gels were then covalently decorated with full-length bovine
collagen I at a fixed density using the photoactivatable crosslinker
sulfo-SANPAH. For TFM, maps of substrate displacement and
strain were computed from bead positions before and after cell
detachment using Fourier transform traction cytometry [22].
Atomic Force Microscopy (AFM)
The indentational elasticity of cells cultured on either collagen-
coated PA hydrogels or glass coverslips were measured with an
Asylum MFP 3-D AFM (Asylum Research, CA) as described
previously [20].
Results
Localization and Suppression of a-Actinin Isoforms in
Cultured Glioma Cells
To establish baseline expression and localization of a-actinin
isoformsinahumangliomacelllinewehadpreviouslydemonstrated
to be mechanosensitive [7], we cultured U-373 MG human glioma
cells on collagen I-coated glass coverslips and examined isoform
distributions by immunofluorescence. While U-373 MG glioma cells
were found to exhibit a wide heterogeneity in cell morphology,
consistent with our and others’ previous reports, membrane ruffles
were observed in ,48% of cells. In this population of cells, both a-
actinin-1 and a-actinin-4 localized strongly to membrane ruffles
(Figure 1A). In addition, a-actinin-1 stained in a focal adhesion-like
distribution in ,70% of cells and colocalized with stress fibers in
,35% of cells. In comparison to a-actinin-1, a-actinin-4 localized
along stress fibers in ,45% of cells. We next suppressed expression
a Actinin and Mechanobiology
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and siACTN4 respectively) and compared the results of each
treatment on expression and subcellular localization to each other
and to a scrambled siRNA control sequence (siCTL) (Figure 1B).
Individual isoform-specific siRNA sequences and transfection
conditions were optimized to obtain ,55% depletion of a-actinin-
1a nd,60% depletion ofa-actinin-4byimmunoblot,comparableto
levels of suppression achieved in previous studies with minimal off-
target effects [18]. Consistent with this incomplete knockdown, a-
actinin-1 and a-actinin-4- depleted cells still stained weakly positive
for a-actinin-1 and a-actinin-4 respectively (Figure 1C, Figure S1).
Although depletion of one isoform did not cause compensatory
changes in expression of the other isoform, a-actinin-1 suppression
led to partial redistribution of a-actinin-4 to FAs (arrows). This was
also confirmed by co-staining cells with isoform-specific a-actinin
antibodiesandanantibodyagainstthephosphorylatedTyrosine-397
of focal adhesion kinase (pY397FAK), a marker of mature focal
adhesions (Figure S1).
a-Actinin Isoforms Contribute to Glioma Cell Motility
We next quantified the effect of depleting each a-actinin isoform
on cell motility in vitro by tracking the random migration of control
and knockdown cells using phase-contrast time-lapse imaging
(Figure 2, Movies S1, S2, S3). The contributions of individual a-
actinin isoforms to glioma motility were quantified by calculating
Figure 1. Expression, localization, and suppression of a-actinin isoforms in glioma cells. (A) Localization of a-actinin-1 and a-actinin-4 in
U-373 MG cells cultured on collagen-coated glass. Solid and open arrowheads mark the localization of individual a-actinin isoforms at ruffles and
along actin stress fibers, respectively. Scale Bar=10 mm. (B) Measurement of siRNA efficacy by Western Blot of U-373 MG cells transfected with either
scrambled control siRNA (siCTL) or siRNA directed against a-actinin-1 (siACTN1) or a-actinin-4 (siACTN4) (*p,0.05). (C) Subcellular localization of a-
actinin-1 and a-actinin-4 following siRNA treatment. Arrowheads depict the redistribution of a-actinin-4 to FAs when a-actinin-1 is suppressed. Scale
Bar=20 mm.
doi:10.1371/journal.pone.0008427.g001
Figure 2. Contributions of a-actinin isoforms to glioma cell
motility. Effect of a-actinin depletion on mean speeds (mean6SEM,
*p,0.001) of cells tracked over 6 hours.
doi:10.1371/journal.pone.0008427.g002
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(Figure 2). We found that knockdown of either isoform caused a
,35% reduction in mean cell speed relative to control, indicating
that both a-actinin-1 and a-actinin-4 contribute to glioma cell
motility.
a-Actinin Isoforms Contribute to ECM Rigidity Sensing by
Glioma Cells
To test the hypothesis that a-actinin-1 and a-actinin-4
participate in sensing mechanical cues from the ECM and
regulating the shape plasticity of glioma tumor cells, we cultured
control, a-actinin-1-depleted, and a-actinin-4-depleted cells on a
series of collagen I-coated polyacrylamide ECMs spanning a range
of elasticities and compared the dependence of projected cell
spreading area and cortical stiffness on ECM elasticity (Figure 3).
Similar to other cell systems [21,24,25], control cells spread poorly
on relatively compliant ECMs (,5 kPa), more extensively on
stiffer ECMs (8–20 kPa), and to a maximal area above a threshold
ECM stiffness (.20 kPa). (Figure 3A). In contrast, both a-actinin-1
anda-actinin-4depletedcellsspreadlessextensivelythancontrolsat
low ECMstiffness, with up to ,25% reduction in spreading area on
the most compliant ECMs. On intermediate-stiffness (,8 kPa) gels,
both a-actinin-1 and a-actinin-4 depleted cells were less spread
compared to controls, with a-actinin-4 depleted cells spreading
,40% more than a-actinin-1 depleted cells. On the stiffest gels and
on glass, both a-actinin-1 and a-actinin-4-depleted cells achieved
spreading areas comparable to control cells.
Consistent with the increase in spreading area from soft
(,2 kPa) gels to intermediate-compliance (,8 kPa) gels, the
cortical stiffness of control cells increased from ,2.6 kPa on the
soft gels to ,6 kPa on 8 kPa gels, without any further increases in
cortical stiffness with increasing ECM stiffness (Figure 3B). This
adaptation of cortical stiffness to ECM stiffness has been observed
previously in both cultured fibroblasts [26] and mesenchymal stem
cells [27]. Knockdown of either a-actinin isoform blunted this
stiffness adaptation and significantly reduced cortical stiffness for
all ECM stiffnesses. On the most compliant (2 kPa) ECMs, the
stiffnesses of a-actinin-1 and a-actinin-4 depleted cells were
,1.75 kPa and ,1.5 kPa respectively, representing a ,40%
reduction in stiffness compared to controls. On the stiffest ECMs
(.18 kPa), the cortical stiffness of both a-actinin-1 and a-actinin-4
depleted cells achieved a plateau stiffness of ,2.7 kPa, represent-
ing a ,55% deficiency in cortical stiffness relative to control cells.
Taken together, these results demonstrate that each a-actinin
isoform plays a critical role in the shape plasticity and adaptation
of glioma cells to micromechanical cues, with both isoforms
contributing optimally to cell spreading on compliant ECMs and
cortical stiffness on stiff ECMs.
a-Actinin Suppression Increases Vinculin Expression and
Recruitment to FAs
The previous results illustrate that while depletion of either a-
actinin isoform significantly reduces cortical stiffness and disrupts
actin cytoskeletal architecture, the effects on cell spreading area are
surprisingly modest, particularly at high ECM stiffness. To test if
this might be explained by compensatory upregulation and
redistribution of other FA proteins, we tracked the expression and
subcellular localization of vinculin following knockdown of each
isoform (Figure 4A, Figures S2 and S6). Depletion of either a-
actinin-1 or a-actinin-4 led to enhanced vinculin expression by
Western Blot, with an increase of ,40% in a-actinin-4 knockdown
cells, and a more robust increase of ,55% in a-actinin-1-depleted
cells relative to control. Moreover, confocal imaging revealed
differences in the number and distribution of vinculin-positive FAs,
with a-actinin-1-depleted cells assembling significantly greater
numbers of vinculin-positive FAs relative to controls (Figure 4B).
Although depletion of a-actinin-4 also enhanced vinculin-positive
adhesions relative to control, morphometric analysis revealed that
these FAs were smaller and less numerous than in a-actinin-1
depleted cells (Figure 4C). Interestingly, FAs in a-actinin-1-depleted
and a-actinin-4-depleted cells were also more elongated than in
controls, suggesting that a-actinin depletion yields more mature
adhesions (Figure 4D) that also contain pY397FAK (Figure S3).
Interactions between a-Actinin Isoforms and Activators
of Myosin-Based Contractility
The localization of many mechanosensory FA proteins has been
shown to specifically depend on activation of myosin motors, which
in turn governs cytoskeletal contractility or prestress [28,29]. To
Figure 3. Contributions of a-actinin isoforms to cell-ECM
rigidity sensing. (A) Projected cell-ECM adhesion area of siCTL
(squares), siACTN1 (circles), and siACTN4 (triangles) cells on collagen I-
coated polyacrylamide ECMs of varying elasticity. Cell spreading
differences between control and a-actinin depleted cells are statistically
significant (p,0.001) for both isoforms on 2 kPa and 8 kPa ECMs. (B)
Cortical cell elasticity of siCTL, siACTN1, and siACTN4 cells on variable-
rigidity ECMs by AFM. Differences in cortical elasticity between control
and a-actinin-depleted cells are statistically significant (p,0.001) for all
ECM stiffness.
doi:10.1371/journal.pone.0008427.g003
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the localization of these two isoforms in the presence of
pharmacologic inhibitors of MLCK, ROCK, and NMMII, all
key components of the myosin-based contractility pathway
[30,31,32]. As expected, Western Blots revealed that treatment of
U-373 MG cells with ROCK and MLCK inhibitors markedly
reduced levels of MLC phosphorylation relative to either untreated
controls or cells in which NMMII ATPase was directly inhibited
(Figure S4). While inhibition of MLCK did not lead to dramatic
morphological changes (Movie S4), inhibition of either ROCK or
NMMII significantly altered cell morphology, with cells exhibiting
active membrane ruffles at their leading edges and extending long
membrane processes at their trailing edges, consistent with previous
observations in other cell systems, including glioma cells (Movie S5)
[33,34].
Because both a-actinin isoforms appear to strongly regulate
glioma cell motility and glioma cells are sensitive to contractility
inhibitors, we reasoned that each contractility inhibitor might
differentially oppose or potentiate the reduction in motility
observed upon depletion of each isoform. To explore this
possibility, we studied the motility of glioma cells under MLCK
or ROCK inhibition and in the setting of isoform-specific a-
actinin depletion (Figure 5, Movies S6, S7, S8, S9). MLCK
inhibition modestly reduced (4%) migration speeds of control cells
but did so much more significantly in the setting of either a-
actinin-1 (,60%) or a-actinin-4 (,40%) suppression. Thus, both
a-actinin isoforms act synergistically with MLCK to promote cell
motility. In contrast to MLCK, ROCK inhibition enhanced mean
migration speeds by ,25% relative to controls. While this
enhancement of cell speed was suppressed slightly but not
significantly in a-actinin-1 depleted cells, a-actinin-4 depletion
reduced migration speeds to values similar to untreated cells,
indicating that the enhancement in cell motility observed with
ROCK inhibition may be partially attributed to a-actinin-4.
Contributions of a-Actinin Isoforms to Myosin Expression
and Function
The above results suggest a close association between a-actinin
isoforms and NMMII, whose activation is classically associated with
increased contractility, increased stiffness, and generation of traction
forces [35,36,37]. To testwhether our observed a-actinin-dependent
changes in cellular motility and mechanics were secondary to
Figure 4. Reciprocal relationship between a-actinin and vinculin expression and recruitment to FAs. (A) Effect of a-actinin isoform
suppression on vinculin expression by Western Blot. Vinculin expression is significantly lower (*p,0.05) in both a-actinin-1 and a-actinin-4-depleted
cells than in control cells. (B) Effect of a-actinin depletion on vinculin localization. Both a-actinin-1 and a-actinin-4 depleted cells contain more
vinculin-positive FAs (arrows) than controls. Scale bar=20 mm. (C) Quantitative analysis of size and number of vinculin-positive adhesions. The right-
shift of the siACTN1 and siACTN4 data relative to control demonstrates that both a-actinin-1 and a-actinin-4 depleted cells possess larger and more
numerous adhesions than controls. (D) Circularity of vinculin-positive FAs of siCTL, siACTN1 and siACTN4 cells (*p,0.001). In all cases, data are
mean6SEM.
doi:10.1371/journal.pone.0008427.g004
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expression and phosphorylation in control and a-actinin-depleted
cells (Figure 6A, Figures S5, S6). Indeed, suppression of either a-
actinin-1 or a-actinin-4 reduced myosin expression, with a reduction
of ,66% in a-actinin-1 knockdown cells and ,60% in a-actinin-4
depleted cells relative to control. As expected, suppression of either
isoform also led to reduced levels of MLC phosphorylation (pMLC)
(FigureS5).Tofurtherdeterminethefunctionaleffectofthisreduced
NMMII expression in a-actinin depleted cells on traction force
generation, we used traction force microscopy to compare cell-ECM
tractional forces between control and a-actinin-depleted cells on
ECMs with elasticites of 2 kPa and 18 kPa, respectively (Figure 6B).
This method measures cellular tractional forces (a measure of
contractility) by tracking relaxation of ECM-embedded fiduciary
markers following cell detachment. On the soft (2 kPa) gels, the
mean traction force of control cells, a-actinin-1, and a-actinin-4-
depleted cells were 150 Pa, 85 Pa, and 95 Pa, respectively, with
knockdownofeithersubuniteliminatingthehigh-traction(.250 Pa)
population observed in control cells (Figure S7). Interestingly, the
reduction in mean traction forces closely mirrored the 40%
reduction in cell stiffness of actinin-depleted cells observed on
2 kPa gels (Fig. 3). On the stiffer (18 kPa) gels, the mean traction
force values shifted to 700 Pa, 540 Pa, and 580 Pa, respectively, and
knockdown of either subunit rendered cells unable to generate
tractional forces .1.2 kPa. Taken together, these results show that
depletion of either a-actinin isoform leads to suppression of NMMII
expression and function.
Discussion
We have examined the contributions of the non-muscle a-
actinin isoforms 1 and 4 to the mechanobiology of human glioma
cells. We find that these two isoforms localize to different
subcellular compartments, and that depletion of either isoform
leads to an unexpected increase in vinculin expression and
localization to adhesions, which is accompanied by reduced
motility. We also show that both isoforms serve mechanosenory
functions, with depletion compromising the ability of glioma cells
Figure 6. Effect ofa-actinin expressiononmyosin expressionand
contractility. (A) Effect of a-actinin suppression on NMMII expression by
Western Blot. NMMII expression is significantly lower (*p,0.05) in both a-
actinin-1 and a-actinin-4-depleted cells than in controls. (B) Effect of a-
actinin depletion on traction force generation measured by traction force
microscopy. Box-whisker plots of root-mean squared (RMS) traction of
siCTL,siACTN1 andsiACTN4 cells on 2 kPa and18 kPaECM substrates. The
error bars mark the maximum and minimum of the data sets, the three
horizontal lines mark the 25th, 50th, and 75th percentile of the data, and
the point marks the mean. N.10 cells in all cases.
doi:10.1371/journal.pone.0008427.g006
Figure 5. Differential sensitivity of a-actinin-depleted cells to
contractile inhibitors. Mean speeds of control, a-actinin-1-depleted,
and a-actinin-4-depleted cells for 6 hr following 1 hr of incubation with
10 mM ML7 or 10 mM Y27632. Compared to motility of ML7 treated
control cells, knockdown of either isoform significantly reduces cell
motility (**p,0.001). Depletion of a-actinin-4 (*p,0.05), but not of a-
actinin-1, reduces the motility of Y27632 treated cells to levels observed
in untreated cells.
doi:10.1371/journal.pone.0008427.g005
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rigidity. Mechanistic insight into these findings comes from the
observation that suppression of either a-actinin isoform reduces
expression of NMMII, thereby altering mechanochemical feed-
back between tumor cells and the ECM and reducing maximal
traction forces. Taken together, our data support a model in which
a-actinin isoforms participate in mechanochemical feedback
between glioma cells and the ECM, with expression and
localization of these molecules regulating NMMII-dependent
processes, including adhesion, motility, stiffening, and contractil-
ity. While these results are clear, two points are worth noting: First,
the detailed mechanisms that link suppression of a-actinin to
altered cell migration and mechanics remain to be elucidated, and
it is likely that other elements of the adhesive and contractile
machinery besides NMMII and vinculin play important roles.
Second, we chose not to attempt to rescue effects of a-actinin-
depletion by overexpressing exogenous a-actinin, both because
low double-transfection efficiencies make obtaining meaningful
statistics from single-cell measurements challenging, and because
a-actinin overexpression has previously been observed to pheno-
copy a-actinin depletion (e.g., with respect to cell migration, as
described in the introduction). Thus, we cannot completely rule
out the possibility that some of our observed effects may be due in
part to secondary effects of a-actinin depletion.
Our findings may bear implications for GBM invasion in vivo.
The direct role of NMMII in GBM invasiveness was first
demonstrated by studies in which treatment with MLCK inhibitors
completely abrogated glioma motility [6]. Three isoforms of
NMMII are known to exist (NMMIIA, B, C); NMMIIA is
upregulated in human glioma xenografts, and both NMMIIA and
NMMIIB are required to squeeze through pores smaller than the
size of nuclei [38]. Our studies reveal a causal connection between
a-actininandNMMII inwhichdepletionofeithera-actininisoform
reduces NMMII expression. This close interplay between a-actinin
and NMMII in modulating contractility is consistent with
biophysical studies of gels composed of F-actin, NMMII and a-
actinin, which have found that bulk contractility of the gel occurs
only above a threshold a-actinin concentration [39]. The actin-
crosslinking activity of NMMII in the initial stages of adhesion has
been demonstrated in recent studies where overexpression of wild-
type NMMII in a-actinin-depleted CHO cells was able to restore
adhesion maturation [40]. In human aortic endothelial cells, the
increase in cell prestress obtained with knockdown of a-actinin-1
suggests that a-actinin depletion increases actomyosin interactions
and raises the possibility that a-actinin and NMMII compete for
commonbindingsitesincrosslinkingF-actin[41].Thecellsoftening
observed in our studies upon a-actinin knockdown is also consistent
with a published report in which microinjection of a-actinin not
only increased the stiffness of 3T3 fibroblasts but also the degree of
mechanical heterogeneity of the cytoplasm, as measured by particle
tracking microrheology [42].
Cell migration requires the coordinated extension of membrane
protrusions, formation of transient adhesions along the membrane
extensions, and NMMII-dependent detachment of the cell rear
[43]. The activity of NMMII is controlled by MLC phosphory-
lation, and recent efforts to elucidate regional variations in MLC
phosphoregulation have suggested that MLCK preferentially
regulates dynamic adhesions at the cell periphery and that ROCK
regulates more stable FAs at the cell center [44,45]. We find that
motility is reduced most dramatically by suppressing those
isoforms and inhibiting MLCK. Because the rapid turnover of
FAs at the leading edge needed for migration depends on MLC
phosphorylation, we hypothesize that MLCK utilizes both a-
actinin isoforms in order to promote motility. Similarly, because
the enhancement in motility observed upon ROCK inhibition is
reduced by a-actinin-4 depletion, we suspect that this enhance-
ment may require mobilization of a-actinin-4. Potential mecha-
nisms for this effect might include increased interaction between a-
actinin-4 and pMLC, which translocates to membrane protrusions
in a Rac-dependent manner [46].
The adaptation of glioma cells to changes in ECM stiffness
observed here is reminiscent of the finding that cultured fibroblasts
match their stiffness to the underlying ECM substrate for ECM
stiffnesses up to 5 kPa and reach a maximal stiffness on ECM
substrates [26]. The failure of a-actinin-depleted cells to exhibit
this stiffness adaptation may be due to the requirement for a-
actinin to crosslink cortical actin and stabilize connections between
F-actin and b integrin subunits in adhesions, which would be
expected to require strongest reinforcement on high-rigidity
ECMs, which support large traction forces [47]. Conversely, both
a-actinin isoforms contribute most strongly to spreading area at
low ECM rigidity. We speculate that this may be due to the
compensatory effects of vinculin, whose expression and localiza-
tion to FAs significantly increase on rigid ECMs in the setting of a-
actinin suppression, thereby preserving cell shape but not
necessarily cortical stiffness. This concept is supported by previous
studies in which vinculin suppression reduced spreading, stress
fiber formation, FA formation, and lamellipodial extension [48].
This compensatory effect may itself depend on ECM rigidity, such
that a-actinin-depleted cells cultured on compliant ECMs are
much less capable of recruiting additional vinculin to FAs than
their counterparts on rigid ECMs. As a result, we observe
negligible deficiencies in cell spreading of a-actinin depleted cells
on stiff substrates but see these differences amplify as matrix
stiffness is reduced. Enhanced expression of a-actinin may switch
GBM tumor cells from a strongly adhesive and low-motility
phenotype to a highly contractile and invasive phenotype, and the
possibility that invading glioma cells may stiffen the brain
parenchyma as they invade [7] suggests a complex interplay
between ECM rigidity, a-actinin, and vinculin.
One particularly unexpected finding from these studies is that a-
actinin-depleted cells spread extensively on stiff ECMs despite
having relatively low NMMII expression and low cellular stiffness
and prestress. While this result may be inconsistent with the
conventional notion that high cellular traction is always needed
to support spreading, it is not without precedent. For example,
Janmey and coworkers recently reported that under some
conditions, filamin A-null cells increase their spreading in response
to increasing ECM stiffness while maintaining a relatively constant
cell stiffness [49], indicating that stiffness and spreading are not
strictly coupled. Similarly, we recently showed that when U-373
MG cells cultured on highly compliant ECMs are treated with
ROCK or NMMII inhibitors, which presumably reduce contrac-
tility, they paradoxically begin to spread and migrate [7]. These
and other studies suggest the possibility that specific actin
crosslinking proteins may modulate the degree of coupling
between cell spreading and cellular contractility.
In conclusion, we have investigated the contributions of a-
actinin-1 and a-actinin-4 to mechanobiological behaviors of
human glioma cells and shown that suppressing each isoform
bears significant but distinct implications for tumor cell morphol-
ogy, motility, mechanics, rigidity-sensing, and force generation. As
described earlier, expression of a-actinin has been strongly
correlated with invasive behavior of tumor cells in GBM and
other cancers, although the roles of each isoform remain unclear.
Our findings raise the exciting possibility that enhanced expression
of a-actinin isoforms in tumors could speed motility in vivo by
allowing increased NMMII-generated tractional forces against the
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cues. Since our level of actinin suppression is partial, some of our
observations may be consequences of altered myosin or vinculin
expression. However, it is also possible that modulation of a-
actinin expression in vivo may trigger compensatory changes in
the expression and function of other FA proteins, as we observe in
culture. Testing this hypothesis will require asking whether
normalizing a-actinin overexpression can reduce invasive behavior
in vivo. Given the importance of NMMII to navigating micro-
structural barriers in 3D ECMs, it will also be important to revisit
these behaviors in the context of 3D ECMs that present more
complex combinations of mechanical and topological cues.
Supporting Information
Figure S1 Immunofluorescence co-localization of pY397FAK
with (A) a-actinin-1 and (B) a-actinin-4 following siRNA-mediated
suppression of each a-actinin isoform in U-373 MG cells.In both
(A) and (B), the left, middle, and right columns show results for
control, a-actinin-1 and a-actinin-4-directed siRNAs, respectively.
In each case, the top, middle, and bottom rows show
immunolocalization of the relevant a-actinin isoform (green),
pY397FAK (red), and the merged signal, respectively. Scale
Bar=20 mm.
Found at: doi:10.1371/journal.pone.0008427.s001 (6.13 MB TIF)
Figure S2 Immunofluorescence localization of vinculin (red) in
control cells (siCTL) (left column), a-actinin-1-depleted cells
(siACTN1) (middle column), and a-actinin-4-depleted cells
(siACTN4). Five representative images of each category are
shown. Scale Bar=20 mm.
Found at: doi:10.1371/journal.pone.0008427.s002 (7.44 MB TIF)
Figure S3 Immunofluorescence localization of pY397FAK in
control cells (siCTL) (left column) a-actinin-1-depleted cells
(siACTN1) (middle column) and a-actinin-4-depleted cells
(siACTN4) (right column). Cells have been co-stained for
pY397FAK (red) and F-actin (green). Scale Bar=20 mm.
Found at: doi:10.1371/journal.pone.0008427.s003 (7.36 MB TIF)
Figure S4 Effect of nonmuscle myosin II pathway inhibitors on
phosphorylated MLC (pMLC) levels in U-373 MG cells by
Western Blot. From left to right, the lanes represent lysates from
untreated controls (CTL), cells treated with 10 mM ML7 (ML7),
cells treated with 10 mM Y27632 (Y27), and cells treated with
10 mM blebbistatin (Blebb). The bottom bands are corresponding
GAPDH loading controls.M ML7 (ML7), cells treated with 10 mM
Y27632 (Y27), and cells treated with 10 mM blebbistatin (Bleb).
The bottom bands are corresponding GAPDH loading controls.
Found at: doi:10.1371/journal.pone.0008427.s004 (1.10 MB TIF)
Figure S5 Effect of a-actinin suppression on pMLC levels by
Western Blot. From left to right, the lanes represent lysates from
cells treated with control siRNA (siCTL), siRNA against a-actinin-
1 (siACTN1), and siRNA against a-actinin-4 (siACTN4). The
bottom bands are corresponding GAPDH loading controls.
Found at: doi:10.1371/journal.pone.0008427.s005 (1.03 MB TIF)
Figure S6 Time course of effect of a-actinin-1 suppression on
expression of vinculin and NMMII by Western Blot. The leftmost
lane represents lysates from cells treated with control siRNA for
8 hours (siCTL). Subsequent lanes represent cells treated with
siRNA against a-actinin-1 (siACTN1) for 8, 16, and 24 hours,
respectively. Blots reveal a time-dependent suppression in NMMII
expression (top bands) and a gradual increase in vinculin
expression (middle bands). The bottom bands represent the
GAPDH loading controls.
Found at: doi:10.1371/journal.pone.0008427.s006 (1.18 MB TIF)
Figure S7 Traction maps exerted by siCTL, siACTN1, and
siACTN4 cells on 2 kPa gels. Traction fields have been computed
using Fourier Transform Traction Cytometry. Arrows show the
direction and relative magnitude of traction forces. Color code
shows the magnitude of traction forces in Pa. Note the differences
in scales.
Found at: doi:10.1371/journal.pone.0008427.s007 (6.66 MB TIF)
Movie S1 Phase contrast imaging of U373-MG cells transfected
with control siRNA (siCTL) migrating on collagen-coated tissue
culture plastic over a period of at least 6 hours. Frames were
acquired every 15 min.
Found at: doi:10.1371/journal.pone.0008427.s008 (9.05 MB AVI)
Movie S2 Phase contrast imaging of U373-MG cells transfected
with a-actinin-1 siRNA (siACTN1) migrating on collagen-coated
tissue culture plastic over a period of at least 6 hours. Frames were
acquired every 15 min.
Found at: doi:10.1371/journal.pone.0008427.s009 (9.05 MB AVI)
Movie S3 Phase contrast imaging of U373-MG cells transfected
with a-actinin-4 siRNA (siACTN4) migrating on collagen-coated
tissue culture plastic over a period of at least 6 hours. Frames were
acquired every 15 min.
Found at: doi:10.1371/journal.pone.0008427.s010 (9.05 MB AVI)
Movie S4 Phase contrast imaging of U373-MG cells transfected
with control siRNA (siCTL) and exposed to 10 mM ML7,
migrating on collagen-coated tissue culture plastic over a period
of at least 6 hours. Frames were acquired every 15 min.
Found at: doi:10.1371/journal.pone.0008427.s011 (10.14 MB
AVI)
Movie S5 Phase contrast imaging of U373-MG cells transfected
with control siRNA (siCTL) and exposed to 10 mM Y27632,
migrating on collagen-coated tissue culture plastic over a period of
at least 6 hours. Frames were acquired every 15 min.
Found at: doi:10.1371/journal.pone.0008427.s012 (10.14 MB
AVI)
Movie S6 Phase contrast imaging of U373-MG cells transfected
with a-actinin-1 siRNA (siACTN1) and exposed to 10 mM ML7,
migrating on collagen-coated tissue culture plastic over a period of
at least 6 hours. Frames were acquired every 15 min.
Found at: doi:10.1371/journal.pone.0008427.s013 (10.14 MB
AVI)
Movie S7 Phase contrast imaging of U373-MG cells transfected
with a-actinin-1 siRNA (siACTN1) and exposed to 10 mM
Y27632, migrating on collagen-coated tissue culture plastic over
a period of at least 6 hours. Frames were acquired every 15 min.
Found at: doi:10.1371/journal.pone.0008427.s014 (10.14 MB
AVI)
Movie S8 Phase contrast imaging of U373-MG cells transfected
with a-actinin-4 siRNA (siACTN4) and exposed to 10 mM ML7,
migrating on collagen-coated tissue culture plastic over a period of
at least 6 hours. Frames were acquired every 15 min.
Found at: doi:10.1371/journal.pone.0008427.s015 (10.14 MB
AVI)
Movie S9 Phase contrast imaging of U373-MG cells transfected
with a-actinin-4 siRNA (siACTN4) and exposed to 10 mM
Y27632, migrating on collagen-coated tissue culture plastic over
a period of at least 6 hours. Frames were acquired every 15 min.
Found at: doi:10.1371/journal.pone.0008427.s016 (10.14 MB
AVI)
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